Chinese healthcare reforms may be a double-edged sword for foreign companies.
Brunei harnesses its rich biodiversity and the growing halal market in a bid to develop its pharmaceutical sector.
China's regulatory and compliance environment is set to change as the government declares a crackdown on bribery scandals.
The rising cost of drug development and the decreasing proportion of drug-naive population in the US and European markets are driving international pharmaceutical companies to consider emerging markets as a location to conduct their clinical trials. Asia stands out among the emerging markets given its double-digit growth rates.
Foreign companies zero in on Myanmar with the hope of securing a foothold in its pharmaceutical market.
Industry players brace themselves to face challenges as India's new drug-pricing policy kicks in full gear.
The Taiwanese government engages in regulatory science in a move to boost its pharmaceutical sector.
The Thai government is ramping up efforts to promote and develop the biotechnology sector in a bid to enhance its global competitiveness.
India's biopharmaceutical industry is valued at $2 billion a year with 20 companies producing biosimilars and 50 products available in the domestic market.